Home » Stocks » MYGN

Myriad Genetics, Inc. (MYGN)

Stock Price: $28.25 USD 1.39 (5.17%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 2.17B
Revenue (ttm) 566.10M
Net Income (ttm) -148.00M
Shares Out 76.00M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE 555.56
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $28.25
Previous Close $26.86
Change ($) 1.39
Change (%) 5.17%
Day's Open 27.15
Day's Range 26.99 - 28.82
Day's Volume 398,531
52-Week Range 10.54 - 33.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.

2 days ago - Zacks Investment Research

Myriad (MYGN) delivered earnings and revenue surprises of 40.00% and 11.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to se...

5 days ago - GlobeNewsWire

Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine Company continues...

5 days ago - GlobeNewsWire

New poll shows 83% of people with depression agree life would be easier if others could understand their depression New poll shows 83% of people with depression agree life would be easier if others coul...

1 week ago - GlobeNewsWire

SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will release its financial results for the ...

1 week ago - GlobeNewsWire

SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell t...

1 week ago - GlobeNewsWire

Let's take a look at the three women healthcare MedTech stocks performing well lately.

Other stocks mentioned: BDX, HOLX
4 weeks ago - Zacks Investment Research

Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.

1 month ago - Zacks Investment Research

SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. I...

1 month ago - GlobeNewsWire

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line Lynparza® Maintenance Treatment Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer ...

1 month ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that the Shareholder Class Action Against Myriad Genetics,...

1 month ago - Business Wire

Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.

2 months ago - Zacks Investment Research

Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care Strategic collaboration combine...

2 months ago - GlobeNewsWire

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

2 months ago - Zacks Investment Research

Myriad (MYGN) delivered earnings and revenue surprises of 0.00% and 4.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 152.17% over the past year to ($0.12)...

2 months ago - Benzinga

New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal New talent and promotions span core businesses, transformation, IT, r...

2 months ago - GlobeNewsWire

SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings conference ...

2 months ago - GlobeNewsWire

Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.

2 months ago - Zacks Investment Research

Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those who can sa...

2 months ago - GlobeNewsWire

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming ...

2 months ago - GlobeNewsWire

Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.

2 months ago - Zacks Investment Research

SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today la...

3 months ago - GlobeNewsWire

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Patients with Prostate or Pancreatic Cancer to Benefit  from Treatment with Lynparza

3 months ago - GlobeNewsWire

NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

3 months ago - PRNewsWire

Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.

Other stocks mentioned: ILMN
3 months ago - Zacks Investment Research

Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct link ...

3 months ago - GlobeNewsWire

SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decis...

4 months ago - GlobeNewsWire

These are the stocks posting the largest moves after hours on Tuesday.

Other stocks mentioned: CALM, NKTR, SGH
4 months ago - CNBC

Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth

4 months ago - GlobeNewsWire

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the comp...

4 months ago - GlobeNewsWire

SALT LAKE CITY, Dec. 11, 2020 (GLOBE NEWSWIRE) -- In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS), Myriad Genetics (NASDAQ: MYGN), a global leader in molecular d...

4 months ago - GlobeNewsWire

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

Myriad Genetics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Myriad Genetics Flashes Improved Technical Strength appeared first on...

5 months ago - Investors Business Daily

FRESNO, Calif., Nov. 30, 2020 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, has signed a contract with Myriad Genetics, Inc. (NASDAQ: MY...

5 months ago - PRNewsWire

New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it”

5 months ago - GlobeNewsWire

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice®...

5 months ago - GlobeNewsWire

SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- At the annual meeting of the American College of Rheumatology (ACR), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precisi...

5 months ago - GlobeNewsWire

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

5 months ago - Zacks Investment Research

Myriad Genetics' (MYGN) CEO Paul Diaz on Q1 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Myriad (MYGN) delivered earnings and revenue surprises of 54.55% and 7.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earnings confe...

6 months ago - GlobeNewsWire

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

6 months ago - GlobeNewsWire

About MYGN

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 5, 1995
CEO
R. Bryan Riggsbee
Employees
2,700
Stock Exchange
NASDAQ
Ticker Symbol
MYGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is 26.86, which is a decrease of -4.92% from the latest price.

Price Target
$26.86
(-4.92% downside)
Analyst Consensus: Hold